Vancouver biotech Zymeworks rejects $10.50 per share hostile bid from Dubai hedge fund All Blue

Zymeworks Inc. has rejected an unsolicited takeover proposal from a Dubai hedge fund, saying it “significantly” undervalues the Vancouver biotechnology company and is not in the best interests of …
( read original story …)